Latest news and press releases about Avalo Therapeutics, Inc. (AVTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT.
Price
| Price | $16.58 |
| Market Cap | $872M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.61 |
| EV / EBITDA | -9.25 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -58.03% |
| Return on Invested Capital | -19.44% |
| Return on Assets | -20.44% |
| Gross Margin | -16861.02% |
| Operating Margin | -154844.07% |
| Net Margin | -170055.93% |
Related companies: AARD · BDTX · CHRS · CRBU · ENTA · EPRX · IVA
Explore sector: Healthcare · Biotechnology
More sections of AVTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks